This website is designed to provide information about the Add-Aspirin Trial for both participants and collaborators.
Add-Aspirin is a large randomised clinical trial which is taking place in the UK and India. It will recruit 9,920 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back, avoiding subsequent treatment and preventing deaths.
We aim to recruit 3100 individuals who have had surgery to
remove an early stage breast cancer.
CURRENT STATUS:
NOT YET OPEN
Detailed eligibility criteria will soon be available
We aim to to recruit 2600 individuals who have had surgery to remove an early stage bowel cancer.
CURRENT STATUS:
NOT YET OPEN
Detailed eligibility criteria will soon be available
We aim to recruit 2100 individuals who have had surgery or a
combination of chemotherapy and radiotherapy to remove a cancer of the
stomach or oesophagus (food pipe).
CURRENT STATUS:
NOT YET OPEN
Detailed eligibility criteria will soon be available
We aim to recruit 2120 individuals who have had surgery or
radiotherapy to remove an early stage prostate cancer.
CURRENT STATUS:
NOT YET OPEN
Detailed eligibility criteria will soon be available
A lot of work is currently going on behind the scenes on Add-Aspirin with the aim of opening to recruitment by the end of 2014.
If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial. Individuals will only be able to join the study if the hospital where they are being treated is participating. If you are a healthcare professional who would like to register your hospital’s interest in participating, please send us an email at mrcctu.add-aspirin@ucl.ac.uk